A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) (NCT05885464)
A Phase 1/2, Dose-Exploration and Dose-Expansion Study Evaluating the Safety and Efficacy of Multiplex Base-Edited, Allogeneic Anti-CD7 CAR-T Cells (BEAM-201) in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL. This study consists of Phase 1 dose-exploration cohorts, Phase 1 dose-expansion cohort(s), a Phase 1 pediatric cohort (will enroll patients ages 1 to \< 12 years), and a Phase 2 cohort.
Who can join: Review the eligibility criteria below.
Location: Stanford University School of Medicine — Stanford, California
Age range: 18 Years to 50 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (10 Sites)
- Stanford University School of Medicine — Stanford, California
- Colorado Blood Cancer Institute — Denver, Colorado
- University of Chicago — Chicago, Illinois
- The University of Kansas Cancer Center — Fairway, Kansas
- Dana Farber and Boston Children's Hospital — Boston, Massachusetts
- Cleveland Clinic- Taussig Cancer Center — Cleveland, Ohio
- OHSU Knight Cancer Institute Hematology Oncology — Portland, Oregon
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
- Sarah Cannon- TriStar Bone Marrow Transplant — Nashville, Tennessee
- Methodist Hospital - Texas Transplant Institute — San Antonio, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lymphoblastic Lymphoma
Explore by condition: All Lymphoblastic Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.